Insulet Sales Keep Rising

Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system is worn on the body for approximately three days at a time and allows virtually pain-free automated cannula insertion and blood glucose meter integration. The company is targeting to help 40% of U.S. patients by 2025, and with Omnipod growth tracking well (revenue up 12.4% in the U.S. and 33.1% internationally).

PODD’s fourth-quarter fiscal 2024 saw total revenue pass $2 billion for the first time and enjoyed its ninth consecutive year of 20% or more revenue growth. The company’s growing sales were especially apparent overseas, where PODD has developed markets in several European countries. PODD improved its gross margins to 72.1% as well, largely due to volume, pricing, and manufacturing efficiencies.

It’s no wonder PODD shares are up nearly 58% in a year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Big Money Loving Insulet

Institutional volumes reveal plenty. In the last year, PODD has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in PODD shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Insulet.

Insulet Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, PODD has had strong sales and earnings growth:

• 3-year sales growth rate (+23.6%)
• 3-year EPS growth rate (+1,463.2%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +25%.

Now it makes sense why the stock has been powering to new heights. PODD has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Insulet has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It just made the rare Top 20 report for the first time in a year. The blue bar below shows when PODD was a top pick…ushering in Big Money buying:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Insulet Price Prediction

The PODD rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in PODD at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.